NASH
Insights from experts on how to best navigate the complexity of MASH clinical trials.
The voice of NASH investigators
Global survey provides insights for trial operations
Non-alcoholic steatohepatitis (NASH), a component of metabolic syndrome, is an area of very active clinical development. With no approved therapies to treat NASH, there are more than 130 Phase II or Phase III NASH trials underway or planned.
To help determine the impact of this competitive environment for available and qualified site resources, as well as eligible patients, ICON undertook a global survey of NASH clinical trial sites across 37 different countries.
Digital solutions to alleviate NASH clinical trial challenges
The performance of NASH clinical trials presents many challenges unique to the field. Watch the on-demand webinar to learn about:
- The ability for digital technologies MRI, MRE and whole slide imaging to address NASH clinical trial challenges
- The ability of MRI and MRE to provide timely, high quality non-invasive solutions to enrolment
- The ability of whole slide imaging to facilitate rapid complex workflows that assure consistent high quality assessments of primary efficacy endpoints by enabling expert histopathologists to interact remotely and in real time.
Helping NASH study sites to succeed
Get insights and feedback from our extensive NASH study experience, and the findings from ICON’s survey of more than 2,000 sites across 30 countries including:
- How to best support global NASH sites to succeed in a competitive environment
- Optimising the operational strength of study sites to collectively support the NASH pipeline
- How understanding global and regional nuances can enhance NASH site patient recruitment and operational strategy
Non-Alcoholic Steatohepatitis (NASH) clinical trials
Join Andrew Roche, PhD, a senior member of ICON's NASH team, as he speaks about overcoming the challenges and considerations associated with NASH Clinical Trials and examination of potential strategies to address during trial design or study execution.
NASH solutions
Discover more about ICON's solutions in the development and management of all aspects of NASH clinical trials experts.
-
Media article: Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
Media article: Insight into obesity-related clinical research
In an interview with Contract Pharma, ICON’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
Media article: ICON Announces Results from Survey on Obesity-related Clinical Research
This news article, from Applied Clinical Trials, outlines findings from ICON’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
Media article: ICON Survey Stresses Combo Therapies in Obesity Care
This news piece from The Clinical Trial Vanguard provides an overview of the findings from ICON’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
-
Media article: Diabesity: Implications for treatment and drug development
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
Media article: Special report on liver disease: The phantom menace
ICON's Martin Benson provides expert commentary on liver disease and the challenges faced by clinical researchers.
-
Media article: NASH clinical trials – an outlook on challenges and advances
It’s also believed that a high proportion of NASH patients are undiagnosed because the disease is largely symptomless or causes non-specific symptoms until well advanced.
-
Blog: Challenges and advances in NASH clinical trials
Non-Alcoholic SteatoHepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD).
-
Blog: NASH clearing clinical trial hurdles in race to $35 billion market
Discover more solutions and insights from our experts to address the growing unmet clinical need for NASH treatments.
-
Media article: Liver disease, obesity and the value of treatment
The link between obesity and metabolic-dysfunction associated steatotic liver disease (MASLD), and touches on recent advancements in effective treatments for obesity.
